American Oncology Network (AON) has rolled out a structured program aimed at safely delivering bispecific antibody therapies in community oncology clinics, according to a recent interview with a leading pharmacy professional.
Program design focuses on high‑risk dosing phases
Pharmacy specialist Cherise Steib, PharmD, HDDP described AON’s outpatient bispecific therapy policy as a set of guidelines that emphasize close monitoring during the step‑up dosing period. That stage carries the greatest chance of cytokine release syndrome (CRS) and immune effector cell‑associated neurotoxicity syndrome (ICANS). The policy outlines follow‑up steps and requires patients to acknowledge the potential hazards before treatment begins.
Patients and caregivers receive training from nurses or other clinical staff before the first dose. In these sessions, participants learn to track vital signs and spot early signs of CRS or ICANS. Printed guides and digital tutorials reinforce the lessons, giving individuals a reference point for home‑based monitoring.
Pharmacists anchor the multidisciplinary effort
Pharmacists are tasked with translating the policy into everyday practice. Their duties include educating the care team, helping construct individualized regimens, producing patient‑focused materials, and fielding clinical queries from physicians. When dosage tweaks or toxicity concerns arise, they provide the necessary guidance.
The program also extends support beyond the clinic. Selected individuals may self‑monitor at home while retaining access to on‑call providers for urgent issues. AON has drafted guidance for external hospitals and emergency departments to aid in recognizing and managing CRS or ICANS if a patient presents there.
Coordination among nurses, providers, patients, and caregivers is presented as essential for preparing clinics, handling treatment‑related risks, and sustaining support throughout therapy.
Related: User blocked from platform after violation
One notable aspect of the program is its reliance on patient‑driven data collection. By empowering individuals to record symptoms and vital signs, the network hopes to catch complications earlier than traditional clinic‑based checks would allow. This approach, while demanding on individuals, could streamline care pathways and alleviate pressure on infusion centers.
Nevertheless, the initiative reflects a broader shift toward decentralizing advanced cancer therapies, moving them from specialized hospitals into more accessible community environments. The program’s emphasis on multidisciplinary coordination aligns with industry trends that prioritize safety while expanding treatment options.
According to the interview, AON’s protocol includes clear escalation steps for urgent concerns, ensuring that individuals have a direct line to clinical expertise even when outside the primary clinic. This safety net is designed to mitigate the risks associated with the rapid onset of CRS and ICANS, which can develop within hours of dosing.
As bispecific antibodies continue to gain traction in oncology, programs like AON’s may serve as templates for other networks seeking to balance efficacy with patient safety in outpatient contexts.
The model aims to save lives.